RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+19.66%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$940M
AUM Growth
-$118M
(-11%)
Cap. Flow
-$198M
Cap. Flow
% of AUM
-21.11%
Top 10 Holdings %
Top 10 Hldgs %
62.65%
Holding
57
New
1
Increased
–
Reduced
32
Closed
9
Avg Time Held
4.2
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hinge Health
HNGE
|
+$12.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amicus Therapeutics
FOLD
|
+$53.9M |
| 2 |
Scholar Rock
SRRK
|
+$14.7M |
| 3 |
Boston Scientific
BSX
|
+$10.9M |
| 4 |
Krystal Biotech
KRYS
|
+$10.9M |
| 5 |
Cogent Biosciences
COGT
|
+$9.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
DELISTED
Verve Therapeutics
VERV
| $8.31M | 0.88% |
740,261
-466,903
| -39% | -$2.66M |
2021 Q2
16 quarters
|
|
27
CeriBell Inc
CBLL
$1.01B
| $8.15M | 0.87% |
435,239
| – | – |
2024 Q4
2 quarters
|
|
28
Keros Therapeutics
KROS
$219M
| $7.38M | 0.79% |
552,506
| – | – |
2024 Q1
5 quarters
|
|
29
Celldex Therapeutics
CLDX
$2.19B
| $6.98M | 0.74% |
343,026
-247,149
| -42% | -$4.81M |
2020 Q2
20 quarters
|
|
|
30
DELISTED
Amicus Therapeutics
FOLD
| $6.81M | 0.73% |
1,188,998
-8,344,671
| -88% | -$53.9M |
2013 Q2
48 quarters
|
|
31
Nuvation Bio
NUVB
$1.64B
| $5.91M | 0.63% |
3,031,009
| – | – |
2021 Q1
17 quarters
|
|
32
Establishment Labs
ESTA
$1.72B
| $5.83M | 0.62% |
136,495
-198,871
| -59% | -$6.94M |
2024 Q1
5 quarters
|
|
33
Prime Medicine
PRME
$568M
| $5.12M | 0.55% |
2,074,350
| – | – |
2022 Q4
10 quarters
|
|
34
DELISTED
RAPT Therapeutics
RAPT
| $5.05M | 0.54% |
630,686
-178,729
| -22% | -$1.36M |
2022 Q1
13 quarters
|
|
35
Penumbra
PEN
$12.6B
| $4.83M | 0.51% |
18,818
-4,025
| -18% | -$1.1M |
2024 Q3
3 quarters
|
|
36
Shattuck Labs
STTK
$535M
| $4.39M | 0.47% |
5,539,724
| – | – |
2020 Q4
18 quarters
|
|
37
Atara Biotherapeutics
ATRA
$96M
| $3.41M | 0.36% |
441,701
| – | – |
2014 Q4
42 quarters
|
|
38
DELISTED
IGM Biosciences
IGMS
| $3.31M | 0.35% |
2,952,131
| – | – |
2019 Q3
23 quarters
|
|
39
DELISTED
LAVA Therapeutics
LVTX
| $2.74M | 0.29% |
2,074,372
| – | – |
2021 Q1
17 quarters
|
|
40
DELISTED
Ventyx Biosciences
VTYX
| $2.39M | 0.25% |
1,114,529
-455,264
| -29% | -$735K |
2022 Q3
11 quarters
|
|
41
DELISTED
Repare Therapeutics
RPTX
| $2.2M | 0.23% |
1,586,174
-298,215
| -16% | -$389K |
2020 Q2
20 quarters
|
|
42
Xeris Biopharma Holdings
XERS
$1.78B
| $2.11M | 0.22% |
451,099
| – | – |
2018 Q2
28 quarters
|
|
43
Pliant Therapeutics
PLRX
$54.7M
| $1.89M | 0.2% |
1,632,577
-420,982
| -21% | -$595K |
2020 Q2
20 quarters
|
|
44
Invivyd
IVVD
$179M
| $1.63M | 0.17% |
2,285,320
| – | – |
2021 Q3
15 quarters
|
|
45
ALX Oncology
ALXO
$124M
| $1.41M | 0.15% |
3,391,455
-249,379
| -7% | -$126K |
2020 Q3
19 quarters
|
|
46
Boundless Bio
BOLD
$55.2M
| $595K | 0.06% |
589,034
-136,170
| -19% | -$181K |
2024 Q1
5 quarters
|
|
47
4D Molecular Therapeutics
FDMT
$674M
| $416K | 0.04% |
112,168
-885,067
| -89% | -$3.11M |
2024 Q1
5 quarters
|
|
48
Kalaris Therapeutics
KLRS
$50.7M
| $221K | 0.02% |
82,955
| – | – |
2020 Q3
19 quarters
|
|
49
DELISTED
Allakos
ALLK
| – | – |
-856,615
| Closed | -$195K | – |
|
50
DELISTED
Astria Therapeutics
ATXS
| – | – |
-269,078
| Closed | -$1.44M | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q2 2025 Portfolio in Review
As of Q2 2025, Redmile Group held 57 positions worth $940M, down 11% from $1.06B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Redmile Group withdrew a net $198M in Q2 2025, closing 9 positions and reducing 32 holdings. Its most notable exit was Immunovant, an estimated $8.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Redmile Group opened a new position in Hinge Health worth $15.5M.
- Redmile Group's largest Q2 2025 buy was Hinge Health: 300,000 shares worth $15.5M.
- Redmile Group's biggest Q2 2025 reduction was Amicus Therapeutics, cutting an estimated $53.9M.
- Redmile Group fully exited Immunovant in Q2 2025, selling an estimated $8.38M.
- Redmile Group's ten largest holdings make up 63% of its $940M portfolio in Q2 2025.
- Redmile Group opened 1 new position and closed 9 in Q2 2025.
- Redmile Group's portfolio value fell 11% quarter-over-quarter to $940M.
Based on Redmile Group's 13F filing for Q2 2025, filed 14 Aug 2025.